TrialFrontiers in immunology2022

Investigation of the risk factors to predict cytokine release syndrome in relapsed or refractory B-cell acute lymphoblastic leukemia patients receiving IL-6 knocking down anti-CD19 chimeric antigen receptor T-cell therapy.

Wen-Jie Gong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.